353 related articles for article (PubMed ID: 17568658)
1. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.
Ten Boekel E; Böck M; Vrielink GJ; Liem R; Hendriks H; de Kieviet W
Thromb Res; 2007; 121(3):361-7. PubMed ID: 17568658
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
Mischke R
Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
[TBL] [Abstract][Full Text] [Related]
3. The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal.
Bowyer A; Smith J; Woolley AM; Kitchen S; Hampton KK; Maclean RM; VAN Veen JJ; Makris M
Int J Lab Hematol; 2011 Apr; 33(2):212-8. PubMed ID: 20880301
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
Lawrie AS; Kitchen S; Purdy G; Mackie IJ; Preston FE; Machin SJ
Clin Lab Haematol; 1998 Jun; 20(3):179-86. PubMed ID: 9681235
[TBL] [Abstract][Full Text] [Related]
5. A laboratory evaluation into the short activated partial thromboplastin time.
Mina A; Favaloro EJ; Mohammed S; Koutts J
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):152-7. PubMed ID: 20051842
[TBL] [Abstract][Full Text] [Related]
6. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C.
Ten Boekel E; Bartels P
Pathophysiol Haemost Thromb; 2002; 32(3):137-42. PubMed ID: 12372929
[TBL] [Abstract][Full Text] [Related]
7. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity.
Mina A; Favaloro EJ; Koutts J
Blood Coagul Fibrinolysis; 2012 Apr; 23(3):203-7. PubMed ID: 22322136
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
Shetty S; Ghosh K; Mohanty D
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):493-7. PubMed ID: 12851537
[TBL] [Abstract][Full Text] [Related]
9. An Easy Method to Eliminate the Effect of Lupus Anticoagulants in the Coagulation Factor Assay.
Tang N; Yin S
Clin Lab; 2016 Jul; 62(7):1363-1365. PubMed ID: 28164630
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
[TBL] [Abstract][Full Text] [Related]
11. Comparison of six activated partial thromboplastin time reagents: intrinsic system factors' sensitivity and responsiveness.
Hales SC; Johnson GS; Wagner D
Clin Lab Sci; 1990; 3(3):194-6. PubMed ID: 10149038
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
Kitchen S; Woolley A
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
[TBL] [Abstract][Full Text] [Related]
13. Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital.
Chng WJ; Sum C; Kuperan P
Singapore Med J; 2005 Sep; 46(9):450-6. PubMed ID: 16123828
[TBL] [Abstract][Full Text] [Related]
14. [Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization].
Mischke R
Berl Munch Tierarztl Wochenschr; 2002; 115(5-6):225-9. PubMed ID: 12058600
[TBL] [Abstract][Full Text] [Related]
15. Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions.
Barna L; Triplett DA
Ric Clin Lab; 1989; 19(4):345-54. PubMed ID: 2517350
[TBL] [Abstract][Full Text] [Related]
16. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
17. Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event.
Abdullah WZ; Moufak SK; Yusof Z; Mohamad MS; Kamarul IM
Transl Res; 2010 Jun; 155(6):315-9. PubMed ID: 20478546
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
Brandt JT; Arkin CF; Bovill EG; Rock WA; Triplett DA
Arch Pathol Lab Med; 1990 Feb; 114(2):135-41. PubMed ID: 2405809
[TBL] [Abstract][Full Text] [Related]
19. The role of factor XI in a dilute thromboplastin assay of extrinsic coagulation pathway.
He R; Xiong S; He X; Liu F; Han J; Li J; He S
Thromb Haemost; 2001 Jun; 85(6):1055-9. PubMed ID: 11434684
[TBL] [Abstract][Full Text] [Related]
20. Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A.
Scand J Haematol; 1980 Oct; 25(4):308-17. PubMed ID: 6782653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
